Hims & Hers Health reported a $33.04 million net loss

Hims & Hers Health (HIMS) filed a 10-Q with the SEC on Nov 9, 2026, 4:17 pm ET. Source: the filing on SEC EDGAR.

Quarterly report, 7 new risk factors

Written from the 10-Q on EDGAR. AI can make mistakes. Check the filing.

What changed since last quarter

7 new risk factors · 4 removed · 3 new legal mentions

Compared with the 10-Q for the period ended Jun 30, 2026.

New risk factors (7)

•Evolving government regulations and enforcement activities may require increased costs or adversely affect our results of operations. As our operations grow in breadth and scale, we may be unable to keep pace with increasingly complex and extensive compliance and regulatory obligations, which could expose us to…
Groups and us. These laws and regulations are subject to change and enforcement based upon political, regulatory, and other influences, and have been the subject of a recent increase in focus and action by a number of state legislatures. More restrictive treatment of healthcare professionals' relationships with…
We depend on the Affiliated Medical Groups and their Providers to deliver quality healthcare consultations and services through our platform. We conduct fulfillment and distribution activities through a combination of our Facilities and Partner
Advertising of pharmacy services must comply with the guidance of the GPhC and the Medicines and Healthcare products Regulatory Agency (the "MHRA"). Any promotion of prescription medicines must be directed only to healthcare professionals.
In 2026, we began offering testosterone replacement therapy, which is subject to controlled substance laws and regulations. See "—Our offering of testosterone replacement therapy subjects us to additional regulation, and any failure to comply could adversely affect our business."
and 2 more in the filing

Removed risk factors (4)

•Disruption to our global supply chain, including as a result of evolving laws and regulations, can impact our operations in ways that may be difficult to predict or control, may require us to modify or discontinue certain supplier relationships, sourcing strategies, or operational processes, and may result in delays…
trade policies continue to be in flux, and trade policies implemented by the second Trump administration, or the consequences of such policies, could have an adverse effect on our business.
We offer access to compounded pharmaceutical products that are in some cases compounded, fulfilled, and distributed through the Pharmacies, and we, as well as the Pharmacies, Affiliated Medical Groups, and Providers, have faced and in the future may face allegations, litigation, and regulatory investigations under…
In the United States, our compounding activities are subject to FDA and state oversight, and we may face regulatory, compliance, or enforcement risks in connection with our compounded offerings. For instance, compounding pharmacies and

New legal mentions (3)

On October 22, 2026, the Company filed a motion to dismiss the complaint, which is currently set for hearing on January 14, 2027.
On September 1, 2026, a putative securities class action was filed in the U.S. District Court for the Northern District of California against the Company and certain of its executives, captioned Velanki v. Hims & Hers Health, Inc., et al., No. 3:26-cv-09313 (the "Velanki Action"). +1 more paragraph
22, 2025, and alleges violations of securities laws in connection with alleged misrepresentations regarding the Company's business, operations, and prospects, and in particular, with respect to the business relationship between the Company and Novo Nordisk.